Many solid tumors evade immune attack through tumor-associated macrophages (TAMs) that suppress T-cell activity. Immunotherapy for solid tumors, including immune-checkpoint-inhibitor (ICI)-resistant cancers Combination therapy with anti-PD-1/PD-L1 or other immune modulators ... Read more

CAR-T therapies have underperformed in solid tumors because of antigen heterogeneity and a suppressive tumor microenvironment (TME). Our tumor-antigen-agnostic cell therapy locally targets the tumor microenvironment. Universal CAR-T cell therapy for solid tumors Combination therap... Read more

Dysfunctional immune circuits underlie many diseases, including cancer and autoimmunity. Current immunotherapies often target a single pathway or cell type, limiting their efficacy. Treatment of anti-PD-1 refractory solid tumors, including breast, colorectal, lung, and melanoma ca... Read more